Akebia Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKBA research report →
Range $1 – $1
Price Chart
About the company
Akebia Therapeutics, Inc. , established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials.
- CEO
- John Butler
- IPO
- 2014
- Employees
- 194
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on AKBA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $107.04M
- P/E
- -2.64
- PEG
- 0.01
- P/S
- 0.59
- P/B
- 5.74
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 78.89%
- Op Margin
- -15.74%
- Net Margin
- -22.60%
- ROE
- -169.15%
- ROIC
- -14.22%
Latest fiscal year · YoY change
- Revenue
- $236.20M+47.5%
- Gross Profit
- $196.73M+102.8%
- Op Income
- $23.50M
- Net Income
- $-5,345,000+92.3%
- EPS
- $-0.02+93.7%
- OCF Growth
- +267.2%
- FCF Growth
- +266.4%
- 52W High
- $1.73
- 52W Low
- $0.36
- 50D MA
- $0.73
- 200D MA
- $1.09
- Beta
- 0.23
- RSI (14)
- 35
- Avg Volume
- 8.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Akebia said Q3 was driven by strong patient growth in Vafseo, but reported revenue lagged underlying demand because of inventory drawdowns and pricing pressure ahead of post-TDAPA changes.· November 5, 2026
- Total revenue fell to $36.9 million from $58.8 million, mainly because Auryxia declined to $20 million from $42.5 million.
- Vafseo net product revenue was $14.8 million, up from $14.3 million, while management said underlying Q3 end-user demand was $19 million to $20 million.
- Patient growth continued: about 11,500 patients were on Vafseo, and roughly 25% of patients who had discontinued restarted therapy.
- VOICE showed 2,116 patients, a win odds of 1.16, P=0.0016, and 10% lower hospitalizations versus ESA; VOCAL topline also came back positive.
- Cash and cash equivalents were $159.3 million at quarter-end, and management said existing resources plus royalties and planned refinancing should fund the operating plan for at least two years.
Q3 2026 revenue was $36.9 million, down from $58.8 million in Q3 2025. Vafseo net product revenues were $14.8 million versus $14.3 million a year ago, while Auryxia net product revenues were $20 million versus $42.5 million. Cost of goods sold was $6.4 million versus $9.4 million; R&D was $16.2 million versus $14.9 million; SG&A was $23.5 million versus $29.1 million. Net loss was $14.4 million versus net income of $0.5 million in Q3 2025. Cash and cash equivalents were $159.3 million at quarter-end, including $6.6 million in ATM proceeds, up from $155.5 million at June 30, 2026. Management said Q3 underlying Vafseo patient demand was $19 million to $20 million, while Q2 underlying demand had been $17 million to $18 million. For Q4, management expects continued patient growth, led by mid-sized dialysis providers, and said post-TDAPA average annual therapy cost should fall somewhere between $1,000 and $1,500.
John Butler’s main message was that Vafseo is gaining real clinical and commercial traction, but adoption is still moving deliberately, especially at the large dialysis organizations. He highlighted VOICE as a potentially practice-changing outcomes study and said the company believes Vafseo can ultimately become standard of care if it reaches 200,000 to 250,000 patients. On the pipeline, he sounded enthusiastic about praliciguat and especially ebribafusp, calling the rare kidney disease opportunity underappreciated in the stock.
Erik Ostrowski focused on the quarter’s financial mix: total revenue declined to $36.9 million, driven by Auryxia’s drop to $20 million and only modest Vafseo growth to $14.8 million. He noted cost savings in COGS, SG&A, and the lower operating expense base, but R&D rose to $16.2 million because of phase II work for ebribafusp and praliciguat. He also said cash of $159.3 million, plus expected product royalty, supply, and license revenues and a planned refinancing of the senior secured term loan, should support the current operating plan for at least the next two years.
Analysts pressed management on why DaVita and Fresenius adoption has been slower than hoped and what could unlock a bigger rollout. Management said DaVita is being deliberate, is extending its contract, and is influenced by VOICE and now VOCAL, while Fresenius is interested but likely to move more slowly because of organizational change. Questions on VOCAL focused on additional analyses beyond hemoglobin non-inferiority; management said it still expects data on hemoglobin stability, transfusions, rescue therapy, and red blood cell omics, and said those results could inform TIW labeling strategy. On the rare kidney trials, management said praliciguat enrollment is progressing at a competitive pace but without a disclosed timeline, while ebribafusp’s initial data should come sooner and will focus on proteinuria and complement biomarkers without systemic alternative-pathway inhibition.
The bull case is that patient adoption of Vafseo is growing even before broader large-LDO rollout, with about 11,500 patients on therapy and strong interest from physicians who have used it at mid-sized providers. Management believes VOICE and VOCAL strengthen the product story by showing hospitalization benefit and non-inferior hemoglobin control, which could support broader adoption over time. The pipeline also gives the company another shot at value creation, especially if ebribafusp shows the differentiated kidney-disease profile management described.
The biggest risk remains commercialization: revenue is still being held back by inventory drawdowns, lower dose assumptions, dialysis compliance issues, and slower-than-expected uptake at DaVita and Fresenius. Management also expects continued pressure on pricing as ESA and MIRCERA prices fall, with average annual therapy cost expected to land between $1,000 and $1,500 after TDAPA. In addition, the rare kidney programs are still early, with praliciguat timing not yet disclosed and ebribafusp data not expected until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.3%
- Shares Outstanding
- 277.66M
- Float Shares
- 272.81M
of shares held by institutions
177 13F filers
Buy/sell ratio 13.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 21.08M | ▲ 1.10M |
| Vanguard Group Inc | 16.02M | ▲ 468.94K |
| Vanguard Capital Management LLC | 11.33M | ▲ 5.25K |
| Aqr Capital Management LLC | 9.15M | ▲ 7.36M |
| Acadian Asset Management LLC | 8.97M | ▲ 4.97M |
| Geode Capital Management, LLC | 6.35M | ▼ 381.61K |
| State Street Corp | 5.30M | ▼ 95.78K |
| Jacobs Levy Equity Management, Inc | 4.27M | ▲ 3.84M |
| Goldman Sachs Group Inc | 3.69M | ▲ 86.34K |
| Vanguard Portfolio Management LLC | 3.54M | ▲ 1.00M |
| Millennium Management LLC | 3.20M | ▲ 811.89K |
| Two Sigma Investments, LP | 2.44M | ▲ 1.14M |
Held by 140 ETFs
Biggest fund positions in AKBA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 6, 26 | Butler John P. | other | 350,000 |
| Aug 6, 26 | Butler John P. | other | 350,000 |
| Jun 29, 26 | Ostrowski Erik | sell | 56,019 |
| Jun 17, 26 | Wolf Myles | other | 35,700 |
| Jun 17, 26 | Wolf Myles | other | 53,600 |
| Jun 17, 26 | Smith Cynthia | other | 35,700 |
| Jun 17, 26 | Smith Cynthia | other | 53,600 |
| Jun 17, 26 | ROGERS MICHAEL W | other | 35,700 |
| Jun 17, 26 | ROGERS MICHAEL W | other | 53,600 |
| Jun 17, 26 | FRIESON RON | other | 35,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AKBA coverage
Recent articles, reports, and earnings notes.
No research on AKBA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKBA report →Akebia Therapeutic's Vafseo® (vadadustat) Granted Additional Patent
globenewswire.com · Nov 17
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
globenewswire.com · Nov 16
Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Nov 5
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
globenewswire.com · Nov 5
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.